These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19748281)

  • 41. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015.
    Weycker D; Bensink M; Wu H; Doroff R; Chandler D
    Curr Med Res Opin; 2017 Dec; 33(12):2115-2120. PubMed ID: 28958156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.
    Hayama T; Sakurai K; Miura K; Washinosu S; Tsuboi S; Uchiike A; Yoshida Y; Takei M
    Int J Clin Pharm; 2018 Oct; 40(5):997-1000. PubMed ID: 29855985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Timing of Administration of Pegfilgrastim and Prophylaxis for Febrile Neutropenia for Patients with Early Breast Cancer Receiving Chemotherapy].
    Toyoda C; Mizuno Y
    Gan To Kagaku Ryoho; 2024 Feb; 51(2):149-152. PubMed ID: 38449400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments.
    Gascón P; Aapro M; Ludwig H; Rosencher N; Boccadoro M; Turner M; MacDonald K; Muenzberg M; Abraham I
    Crit Rev Oncol Hematol; 2011 Mar; 77(3):198-200. PubMed ID: 21377576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy-induced febrile neutropenia in patients with breast cancer. A multivariate risk assessment model for first cycle chemotherapy.
    Baghlaf SS; Abulaban AA; Abrar MB; Al-Shehri AS
    Saudi Med J; 2014 Jun; 35(6):612-6. PubMed ID: 24888663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study.
    Jurczak W; Kalinka-Warzocha E; Chmielowska E; Duchnowska R; Wojciechowska-Lampka E; Wieruszewska K
    Contemp Oncol (Pozn); 2015; 19(3):214-9. PubMed ID: 26557762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients.
    Timmer-Bonte JNH; Ouwerkerk J; Faber LM; Kerkhofs LGM; Laterveer L; Ten Oever D; van Rees BP; van der Linden PW
    Neth J Med; 2020 Sep; 78(5):270-276. PubMed ID: 33093252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study.
    Laribi K; Badinand D; Janoray P; Benabed K; Mouysset JL; Fabre E; Monchecourt F; Diab R
    Support Care Cancer; 2019 Nov; 27(11):4283-4292. PubMed ID: 30874925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
    Inagaki M; Sato J; Nihei S; Kashiwaba M; Kudo K
    Gan To Kagaku Ryoho; 2016 May; 43(5):593-6. PubMed ID: 27210089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.
    Issa DE; Gelderblom H; Lugtenburg PJ; van Herk-Sukel MP; Houweling LM; De La Orden M; van der Werf-Langenberg ME; Nortier JW; de Jong FA
    Eur J Cancer Care (Engl); 2015 Mar; 24(2):232-41. PubMed ID: 24528512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Management of adverse effects by cancer chemotherapy for treatment of advanced breast cancers].
    Kobayashi T; Fujii T; Yamazaki H; Ohkawa Y; Kuraishi Y; Inagaki J
    Nihon Rinsho; 2000 Apr; 58 Suppl():298-310. PubMed ID: 11026010
    [No Abstract]   [Full Text] [Related]  

  • 53. Breast cancer: Improved care through effective management of febrile neutropenia. Foreword.
    Jones AL; Leonard R
    Br J Cancer; 2009 Sep; 101 Suppl 1(Suppl 1):S1. PubMed ID: 19755999
    [No Abstract]   [Full Text] [Related]  

  • 54. Pegfilgrastim.
    Phillips MS
    Clin J Oncol Nurs; 2003; 7(2):238-9. PubMed ID: 12696226
    [No Abstract]   [Full Text] [Related]  

  • 55. [Breast and Endocrine Tumor Supportive Care for Febrile Neutropenia in Chemotherapy - Current Situation and Future Perspective in Breast Cancer Treatment -].
    Saeki T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2072. PubMed ID: 29361619
    [No Abstract]   [Full Text] [Related]  

  • 56. Budget Impact on the Use of Pegfilgrastim to Reduce the Febrile Neutropenia During Chemotherapy for Breast Cancer with Moderate Risk Compared to a Standard Therapy.
    Choi WS; Lee YJ; Ju SY; Heo SB; Kim CM
    Value Health; 2014 Nov; 17(7):A623. PubMed ID: 27202197
    [No Abstract]   [Full Text] [Related]  

  • 57. Economic Evaluation of Primary Prophylaxis Using Filgrastim Versus Pegfilgrastim in Patients With Solid Tumor Cancer: A Systematic Literature Review.
    Sun D; Gharaibeh M; Altyar A; MacDonald K; Martin J; Abraham I
    Value Health; 2014 Nov; 17(7):A736. PubMed ID: 27202642
    [No Abstract]   [Full Text] [Related]  

  • 58. Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer.
    Lilenbaum R; Samuels M; Taffaro-Neskey M; Cusnir M; Pizzolato J; Blaustein A
    J Thorac Oncol; 2010 Jun; 5(6):837-40. PubMed ID: 20421820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
    Klastersky J; Awada A
    Crit Rev Oncol Hematol; 2011 Apr; 78(1):17-23. PubMed ID: 20227290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.